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Efficacy of different types of cognitive enhancers for patients
with schizophrenia: a meta-analysis
Igne Sinkeviciute1,2,3, Marieke Begemann4, Merel Prikken5, Bob Oranje5, Erik Johnsen1,2,6, Wan U. Lei7, Kenneth Hugdahl1,2,8,
Rune A. Kroken1,2,6, Carina Rau9, Jolien D. Jacobs10, Silvia Mattaroccia11 and Iris E. Sommer4,8
Cognitive impairment is a core feature of schizophrenia, which is predictive for functional outcomes and is, therefore, a treatment
target in itself. Yet, literature on efficacy of different pharmaco-therapeutic options is inconsistent. This quantitative review provides
an overview of studies that investigated potential cognitive enhancers in schizophrenia. We included pharmacological agents,
which target different neurotransmitter systems and evaluated their efficacy on overall cognitive functioning and seven separate
cognitive domains. In total, 93 studies with 5630 patients were included. Cognitive enhancers, when combined across all different
neurotransmitter systems, which act on a large number of different mechanisms, showed a significant (yet small) positive effect size
of 0.10 (k= 51, p= 0.023; 95% CI= 0.01 to 0.18) on overall cognition. Cognitive enhancers were not superior to placebo for
separate cognitive domains. When analyzing each neurotransmitter system separately, agents acting predominantly on the
glutamatergic system showed a small significant effect on overall cognition (k= 29, Hedges’ g= 0.19, p= 0.01), as well as on
working memory (k= 20, Hedges’ g= 0.13, p= 0.04). A sub-analysis of cholinesterase inhibitors (ChEI) showed a small effect on
working memory (k= 6, Hedges’ g= 0.26, p= 0.03). Other sub-analyses were positively nonsignificant, which may partly be due to
the low number of studies we could include per neurotransmitter system. Overall, this meta-analysis showed few favorable effects
of cognitive enhancers for patients with schizophrenia, partly due to lack of power. There is a lack of studies involving agents acting
on other than glutamatergic and cholinergic systems, especially of those targeting the dopaminergic system.
npj Schizophrenia  (2018) 4:22 ; doi:10.1038/s41537-018-0064-6
INTRODUCTION
Cognitive impairment is a core feature of schizophrenia.1 A range
of cognitive functions are affected in patients with schizophrenia,
with a mean decrease of one to two standard deviations (SD)
compared to the general population.2 Cognitive dysfunction can
be present before the onset of psychotic symptoms and after the
first psychosis either remains at decreased levels or declines
further during the illness.3 These deficits are predictive for
functional outcomes, both before and after the first psychotic
episode4,5 and are, therefore, a treatment target of its own.6
Psychological as well as pharmacological treatments have been
suggested for cognitive enhancement in schizophrenia. Cognitive
remediation techniques have been investigated in depth and
have shown small to medium effects, irrespective of active or
passive control groups.7 Antipsychotic medication predominantly
target positive symptoms such as delusions, hallucinations, and
disorganization, and may even have a negative impact on
cognition.8
The pathophysiology of cognitive dysfunctions in schizophrenia
is complex and many different neurotransmission systems are
involved.9 Therefore, pharmacological agents targeting different
putative mechanisms may be relevant for cognitive enhancement.
Pharmacological enhancement of cognition has been a main field
of research in the last decades, investigating different neuro-
transmitter systems and seemingly reporting as many positive as
negative findings. As of yet, there is no clear picture whether any
pharmacological treatment can improve cognitive functioning in
schizophrenia, directly or indirectly by increasing the efficacy of
other treatment modalities, and whether or not further investiga-
tion of specific cognitive enhancers, i.e., pharmacological agents
targeting neurotransmitter systems that are potentially relevant
for improving cognitive impairment, should be encouraged.9
Several meta-analyses and reviews have been conducted
regarding potential cognitive enhancers. One of the most
extensive ones was conducted by Choi et al.10 where the authors
reviewed agents acting on three different neurotransmitter
systems, including glutamatergic, cholinergic, and serotonergic.
However, the majority of systematic reviews either includes one
specific neurotransmitter system only, or do not perform meta-
analytical calculations. We here aim to provide a comprehensive
overview of current literature on cognitive enhancers for
schizophrenia as well as answer the question if and which
cognitive enhancers improve overall cognition or one of the
specific cognitive domains. We summarize the efficacy of
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cognitive enhancers acting on seven different neurotransmitter
systems (including a miscellaneous group), thereby making a
distinction between the different neurotransmitter systems
targeted. Even though the cognitive enhancers act on very
different (and sometimes opposite) brain mechanisms, we also
perform one overarching analysis including all different cate-
gories, as all drugs have the same aim, namely: to improve
cognition. We only included published, high quality, double-blind
studies that compared an enhancer to placebo.
For the discussion, we used the arbitrary cutoff values of effect
sizes > 0.02 as clinically significant and total samples of n < 1000
for an underpowered area of research.
RESULTS
The outcome of literature search is shown in Supplementary
Material S1, demographic information on all included studies is
provided in Table 1. In total, 93 studies with 5630 patients were
suitable for inclusion in the meta-analysis (glutamatergic: k= 27;
cholinergic: k= 32; serotonergic: k= 14; dopaminergic: k= 3;
GABA-ergic: k= 2; noradrenergic: k= 4; miscellaneous: k= 11)
(see Table 1). The mean sample size per study sample was 28.73
(SD= 27.13, range= 4–203), mean age of the participants was
44.15 years (SD= 6.36, as reported by 91 study samples), 68.54%
of the sample were men (as reported by 87 study samples) and
average illness duration was 15.57 years (SD= 6.47, as reported by
63 study samples). The cognitive domains covered in the included
studies are shown in Supplementary Material S2.
Overall analyses combining cognitive enhancers from different
neurotransmitter systems
Combining all cognitive enhancers across different neurotrans-
mitter systems for the efficacy on overall cognition resulted in
51 study samples, with a total of 3635 patients (see Fig. 1).
Cognitive enhancers showed a very small but significant positive
effect size of 0.10 over placebo treatment (p= 0.023; 95% CI=
0.01 to 0.18). The number of missing null studies to render this
positive result to nonsignificance was 105. The significant Q-value
(Q(50)= 70.84, p= 0.028) showed that the variability among
studies was higher than would be expected due to sampling
error, and further examination of subgroup differences is
warranted. Heterogeneity was low to moderate (I2= 29.4%),
indicating that 29% of the dispersion that reflects differences in
the true effect sizes, while the remaining 71% can be attributed to
random sampling error. The funnel plot and Egger’s test (t= 3.95,
p < 0.001) indicated potential publication bias (see Supplementary
Material 3).
In spite of their very small, yet significant effect on overall
cognition, taken as a group, cognitive enhancers had no
significant positive effect on any of the separate cognitive
domains (see Table 2). Furthermore, meta-regression analyses
showed no associations between the effect of cognitive enhancers
on overall cognition and duration of treatment (z=−0.09, p=
0.929) or illness duration (z= 0.67, p= 0.505). The effect sizes for
the cognitive subdomains also showed no relation between
duration of treatment or illness duration (14 regressions, p-values
ranging between 0.107 and 0.927).
Efficacy of cognitive enhancers targeting the glutamatergic system.
Twenty-nine study samples of agents acting predominantly on the
glutamatergic system were grouped into this category. Seventeen
study samples evaluated the effects on overall cognition, showing
a small but significant effect of 0.19 (p= 0.013) (see Fig. 1). The
significant Q-value indicated that the included studies did not
share the same effect size (Q(16)= 28.2, p= 0.030), while
heterogeneity was low to moderate (I2= 43.30%). The funnel plot
and Egger’s test (t= 3.03, p < 0.001) indicated potential
publication bias (see Supplementary Material 4). Furthermore, a
very small effect was found for these agents on working memory,
as compared to placebo (k= 20, Hedges’ g= 0.13, p= 0.040) (see
Supplementary Material S5 and S6).
Further sub-analyses were performed by grouping agents
acting mainly at the glycine site (sarcosine, benzoate, glycine, D-
serine, and D-cycloserine, k= 12 in total), agents targeting the
AMPA receptor (k= 5) and memantine/amantadine agents (k= 6),
(see Supplementary material S5). Glycine site acting agents did
not show superior effects compared to placebo, which may result
from insufficient statistical power. AMPA receptor agonists were
more effective than placebo in improving working memory (k= 5,
Hedges’ g= 0.28, p= 0.030). However, the Q-statistic was
significant and heterogeneity was moderate to large (Q(3)=
8.911, p= 0.030; I2= 66.33%), although no outliers were identified.
Furthermore, the effects of memantine/amantadine on overall
cognition showed a positive trend (k= 6, Hedges’ g= 0.34, p=
0.063), which could reach significance when power increases.
Efficacy of cognitive enhancers targeting the cholinergic system.
Forty-three study samples targeting the cholinergic system could
be included. Meta-analysis did not show superior effects of these
agents compared to placebo, (see Fig. 1 and Supplementary
Material S5 and S6). When excluding challenge studies (i.e., studies
providing only a single dose11–13), results did not change. Sub-
analyses were performed showing no superior effects for
nicotinergic agents (three to twenty studies per domain). When
subdividing into alpha 7 (three to sixteen studies per domain) and
alpha 4 (zero to five studies per domain) nicotinic agonists, no
significant results were found except for alpha 4 nicotinic agonists
showing a more favorable outcome for placebo in problem
solving (k= 5, Hedges’g=−0.175 and p= 0.027). The cholinester-
ase inhibitors (ChEI) showed a small yet significant effect on
working memory (k= 6, Hedges’ g= 0.26, p= 0.031), while no
significant effects were found in the sub-analyses for galantamine
(two to six studies per domain).
Efficacy of cognitive enhancers targeting the serotoninergic system.
Fourteen study samples evaluated cognitive enhancers that target
the serotonergic system. The efficacy of these agents was not
superior to placebo (see Fig. 1 and Supplementary Material S5 and
S6). When performing sub-analyses for (partial) 5-HT1A agonists
(zero to three studies per domain), or antidepressants (zero to five
studies per domain), neither comparison reached significance.
Efficacy of cognitive enhancers targeting the dopaminergic system.
For agents targeting the dopamine system, only four study
samples could be included. Studies could only be combined for
the domain of reasoning, the positive effect size did not reach
significance (k= 4, Hedges’ g= 0.34, p= .072), which could be
caused by insufficient statistical power. For overall cognition, and
the domains of attention, processing speed, and visual learning
and memory, only single studies were available so no mean
weighed effect size could be calculated (individual effect sizes are
noted in Supplementary Material S5).
Efficacy of cognitive enhancers targeting the GABA-ergic system.
Three study samples could be included in the GABA-ergic system.
Mean weighed effect sizes were nonsignificant for this type of
cognitive enhancers as compared to placebo (see Fig. 1 and
Supplementary Material S5 and S6).
Efficacy of cognitive enhancers targeting the noradrenergic system.
Four study samples were included targeting the noradrenergic
system, showing no significant effects on overall cognition or the
separate cognitive domains (see Fig. 1 and Supplementary
Material S5 and S6).
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Efficacy of cognitive enhancers targeting miscellaneous receptor
systems. Seventeen study samples were included in this cate-
gory. The effects of these cognitive enhancers compared to
placebo were nonsignificant (see Fig. 1 and Supplementary
Material S5 and S6). However, when excluding challenge studies,
the placebo group showed a superior effect on attention (k= 12,
Hedges’ g=−0.16, p= 0.038; I2= 0%).
DISCUSSION
Cognitive dysfunction is a key problem in schizophrenia that
largely defines global functioning. Therefore, interventions to
improve cognition are needed urgently. Here, we quantitatively
summarized literature on 93 studies investigating the efficacy of
pharmacological treatment for cognitive impairment in schizo-
phrenia. We reviewed the efficacy of agents acting on seven
categories of different neurotransmitter systems, evaluating over-
all cognition as well as seven cognitive subdomains.
All pharmacological agents combined
The results for cognitive enhancers of all neurotransmitter systems
taken together on overall cognition showed a significant effect.
Although statistical significance was reached, the small size of the
effect prevents a positive recommendation for their clinical use as
of yet, as the small improvement is easily outweighed by the risk
of side-effects. When specific cognitive domains were analyzed,
the effects were close to zero, which indicates that very small
advantages are to be expected of augmentation with an
enhancer.
Efficacy of glutamatergic cognitive enhancers
The glutamatergic system is one of the most investigated systems
in enhancing cognition in schizophrenia. Previous meta-analyses
conducted on agents acting on the glutamatergic system by Tsai
et al.14 showed positive results on cognition measured by the
PANSS cognitive subscale (ES= 0.28, p= 0.002), whereas a meta-
analysis by Choi et al.10 did not find any effect of included agents,
neither on overall cognition nor on cognitive subdomains.
Another meta-analysis by Iwata et al.15 did not find superiority
of glutamate positive modulators over placebo. Although they
reported that AMPA receptor positive modulators did have a
tendency to improve attention/vigilance, this finding did not
survive statistical corrections. All three meta-analyses differed in
terms of included compounds, number of studies and subjects,
which might explain different results. Our meta-analysis included
13 different compounds in 27 studies with a total of 1540 patients.
Thus, our meta-analysis is the largest and includes the most
agents acting on the glutamatergic system compared to previous
Fig. 1 Effects of cognitive enhancers on overall cognitive functioning
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ones. Overall, we concluded that glutamatergic agents provide
some beneficial effects on overall cognition and working memory,
but with questionable clinical importance, given the small effect
sizes of 0.19 for overall cognition and 0.13 for working memory.
Sub-analyses indicated that agents acting on the AMPA site
provided larger effects on working memory (ES= 0.28). In
addition, memantine/amantadine might also be promising, as
the medium effect size for overall cognition bordered on
significance. However, more studies on these specific agents are
needed for final conclusions as these sub-analyses included less
than 1000 individuals and heterogeneity between the studies was
indicated.
Efficacy of cholinergic cognitive enhancers
Several meta-analysis and reviews have been conducted for the
cholinergic system. A recent meta-analysis by Kishi et al.16 found
no significant differences between the effects of antipsychotics
plus add-on anti-dementia drugs or add-on placebo on either
overall cognition or cognitive subdomains. However, the meta-
analysis by Kishi et al. combined cholinesterase inhibitors and
glutamatergic antagonists (memantine), which makes compar-
isons to our sub-analysis complicated. Lewis et al.17 conducted a
meta-analyses of alpha-7 nicotinic agents in neuropsychiatric
disorders, were the majority of studies included schizophrenia
patients. The authors found very modest beneficial effects, where
only a sub-analysis of a subgroup with the most effective doses
reached significance on the overall cognitive index (ES= 0.13, p=
0.02). In our meta-analysis, seven studies had two or three
intervention groups with different doses. We included all
investigated doses, which might explain differences in the results.
In the meta-analysis by Choi et al.10 13 studies investigating
cholinesterase inhibitors (ChIE) were included. The authors found
a trend for a positive effect of ChEI on verbal learning and
memory. Although the number of included studies for verbal
learning and memory are the same, we did not replicate their
results for this domain. The differences of methods between Choi
et al.10 and our meta-analysis could explain this disparity in results.
The review of pharmaceutical cognitive-enhancing agents in
schizophrenia and bipolar disorder by Vreeker et al.18 described
galantamine as promising for schizophrenia. We found a trend for
significant results in processing speed.
In conclusion, some small beneficial effects for cognition might
be achieved by ChEI, especially in the working memory domain,
although the meta-analysis show moderate heterogeneity and a
modest sample size (n= 364). More research is needed on the
effects of galantamine on cognition as the effect size for several
domains were above 0.2 but the meta-analysis for this drug was
also underpowered.
Efficacy of serotonergic cognitive enhancers
For the serotonergic system, a previous meta-analysis by Choi
et al.,10 including five studies of 5HT1A receptor agonists and one
study of 5HT2A antagonist mianserin, did not find any favorable
effects of these agents. However, a previous meta-analysis by
Vernon et al.19 on antidepressants for cognitive impairment in
schizophrenia included 11 studies with agents acting predomi-
nantly on the serotonergic system and found a small effect on
composite cognition score as well as a small effect on executive
function (ES= 0.10, p= 0.01 and ES= 0.17, p= 0.02, respectively).
In line with Vernon et al.,19 we found no positive effects on other
analyzed domains. In conclusion, very small effect sizes and lack of
statistical significance indicate that targeting the serotonergic
system alone might not result in sufficient cognitive enhancement
in patients with schizophrenia, with the possible exception of the
attention domain (ES= 0.23).
Efficacy of dopaminergic cognitive enhancers
Too few studies were suitable for inclusion to investigate
dopaminergic substances as a venue to improve other than
reasoning cognitive domains and, therefore, no conclusions can
be made at this point. This is very unfortunate, as the
dopaminergic system, especially the frontal D1 system is thought
to be central to the cognitive dysfunction seen in schizophrenia.20
Thus, further research on dopaminergic enhancers such as
methylphenidate, is needed urgently.
Efficacy of GABA-ergic cognitive enhancers
For the GABA-ergic system the investigated agent is described as
being selective for GABAA α2 and α3 receptors subunits and
should not be sedating, however, this effect cannot be completely
excluded and could therefore have influenced our results. GABA
hypofunction is thought to underlie at least part of the cognitive
impairment seen in schizophrenia.21 Results from our meta-
analysis should be considered with much caution as only five
domains with eighty two patients in each were analyzed.
Efficacy of noradrenergic cognitive enhancers
Both norepinephrine reuptake inhibitors (atomoxetine, reboxe-
tine) and stimulation of α2A receptors (guanfacine, clonidine) or
blockade of α2C or α1 receptors have been suggested as putative
mechanisms for cognitive enhancement.22,23 However, individual
studies included in our meta-analysis, found no beneficial effects
of norepinephrine reuptake inhibitors (atomoxetine, reboxetine),
whereas guanfacine showed some efficacy. Results from our meta-
analysis are underpowered for this neurotransmitter system, as
only three domains with seventy to seventy five patients per
domain were analyzed.
Efficacy of cognitive enhancers of the miscellaneous category
No beneficial effects for the miscellaneous group or modafinil/
armodafinil subgroup were found. Recent reviews on modafinil
and armodafinil24 and modafinil alone25 reported beneficial
effects in single dose studies for some cognitive domains, in
Table 2. Effects of all combined cognitive enhancers on separate cognitive domains
Cognitive domain Number of studies (k) Patients (N) ES Hedges’s g (95% CI) p-value Q-statistic (df ) I2 Failsafe NR
Overall cognition 51 3635 0.10 (0.01 to 0.18) 0.023 Q(50)= 70.84,p= 0.028 29.41 105
Attention 71 4435 0.01 (0.07 to 0.08) 0.893 Q(70)= 97.73,p= 0.016 28.38 0
PS 71 4782 0.01 (0.04 to 0.07) 0.647 Q(70)= 50.33,p= 0.963 0.00 0
Reasoning 74 4492 0.02 (−0.05 to 0.08) 0.639 Q(76)= 90.38,p= 0.082 19.22 0
Verbal fluency 27 1134 −0.05 (−0.16 to 0.07) 0.400 Q(26)= 22.71,p= 0.649 0.000 0
Verbal L&M 74 4190 0.03 (−0.03 to 0.10) 0.327 Q(73)= 82.75,p= 0.204 11.79 0
Visual L&M 66 4133 0.05 (−0.02 to 0.11) 0.155 Q(65)= 67.04,p= 0.407 3.04 0
WM 80 4649 0.06 (−0.01 to 0.12) 0.069 Q(79)= 93.58,p= 0.125 15.58 0
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particular working memory. All, except one of the reviewed
studies with longer treatment duration found no beneficial effects
of modafinil/armodafinil on cognition. Our results are based on
longer treatment duration studies and indicate no beneficial
effects of modafinil/armodafinil for cognition in patients with
schizophrenia in a longer time frame.
Limitations
Combining pharmacological agents across different neurotrans-
mitter systems increases heterogeneity among studies; however
multiple neurotransmitter systems are involved in cognitive
dysfunction in schizophrenia and all these different classes of
drugs have the same aim (i.e., to improve cognition). Therefore,
we believe that a combined overall effect does provide valuable
information about cognitive enhancers as a group. Most included
studies investigating cognitive enhancers are relatively small and
generally include older individuals in their chronic phase of illness,
while effects may be better in an earlier stage. Furthermore, most
studies provide experimental treatment of short duration and use
performance-based measures of cognition. While older chronic
patients may not benefit from the drugs targeting cognitive
functions, short duration of treatment might not be enough for
the changes to be clinically visible. The choice of cognitive
measurements and selection of composite scores for overall
cognitive functioning might lack sensitivity to detect subtle
changes. If we had also included subjective measures of cognition
(for example, using the PANSS item on cognition), effect sizes may
have been larger, but the results could also have been more
difficult to interpret.
Grouping of the different agents according to their presumed
mechanism of action is rather challenging as some of them have
several different putative receptor targets (for example tropise-
tron, mirtazapine, modafinil) or the mechanisms are not well
known. Yet, given the large diversity in cognitive enhancers that
has been studied in schizophrenia, some grouping is necessary to
draw any meaningful conclusions, as few compounds have been
used in multiple studies. Accordingly, our strategy was to start the
analysis with broad categories based on the putative predominant
neurotransmitter systems involved. However, as some of the
potential enhancers act very differently on the same neurotrans-
mitter system (e.g., the glutamate category include both glycine
site NMDA receptor agonists and NMDA receptor antagonists), we
broke the analyses further down into more selective categories
whenever sample sizes permit.
Another possible limitation is our inclusion of single dose
studies. Although not similar to treatment studies, we think that
these studies do provide valuable data. Nevertheless, for those
analyses where these were included, we performed a sensitivity
analysis after excluding single dose studies.
Different cognitive tests are used in the studies. Issues
concerning test batteries, such as practice effects, ceiling or floor
effects, placebo effects,26 or sensitivity of the test may have
influenced the results. However, these are well known issues and
suggestions for future studies are provided elsewhere.26
Finally, this meta-analysis focused on schizophrenia, schizo-
phreniform and schizoaffective disorder. Schizotypal personality
disorder (SPD) was not included as it is categorized among the
personality disorders in DSM5. SPD does however share some of
the cognitive deficits seen in patients with schizophrenia,
although to a lesser extent. Indeed, several studies of cognitive
enhancers in patients with SPD have shown positive results.27,28 If
SPD had been included in the present meta-analysis the
combined effect sizes might accordingly become somewhat
larger.
Directions for future research
Given the limitations mentioned above, future studies should
consider the following recommendations:
1. Using the optimal dose
Some of the agents have a very narrow therapeutic window,
where too much or too little does not improve cognition but may
in fact worsen it (e.g., agents stimulating D1R
29,30), while for other
agents the optimal therapeutic dose is still uncertain.17,31 For
substances such as d-serine, tropisetron, reboxetine, modafinil,
armodafinil dose finding in small groups is the first necessary step
before large scale RCTs should be started.
2. Including young patients
Most of the studies include chronic patients in a stable phase of
their illness. As chronic patients are usually older, brain plasticity is
likely to be more limited. Since plasticity is highly associated with
cognitive functions, future studies should include a younger
population, specifically when investigating systems mediating
neuroplasticity, such as the GABAergic and glutamatergic system.
3. Treat at least 6 months
MATRICS recommends phase III clinical trials of at least 6 month
duration to be able to determine efficacy and endurance.32
However, most of the trials are significantly shorter. Thus, negative
findings may stem from insufficient duration of treatment.
4. Investigating more homogeneous groups
Patients with schizophrenia display a heterogeneous clinical
picture that is likely to reflect different pathologies at the brain
level. Therefore drugs might have differential effects for sub-
groups of patients. Disentangling the different pathologies
underlying cognitive deficiencies should be a target to better
stratify the different cognitive enhancers in subgroups of patients
that share some common “biomarkers”. Such biomarkers could be
detected with EEG coherence measures (for the GABA system),
with Event Related Potentials on EEG (for example for the
noradrenergic system) or with the Short Latency Afferent
Inhibition test (a combination of TMS over the motor cortex and
an EMG read out, a reflection of cholinergic innervation).33
Taken as a group, we found a significant (small) effect of
cognitive enhancers in patients with schizophrenia. For specific
agents, few positive results emerged. Yet, enhancers acting on the
glutamatergic system showed a small positive effect on overall
cognition and working memory, while treatment with ChIE had a
significant positive effect on working memory, albeit with a small
effect size. Results favoring placebo might represent chance
findings, yet the possibility that alpha4 agents, ChIE and
GABAergic agents might actually worsen some cognitive functions
cannot be rejected. There is still a major lack of reports on agents
acting on other systems, especially the dopaminergic and
noradrenergic systems. Important issues such as dose, treatment
duration, including a younger population and subtyping hetero-




In our systematic search we included different pharmacological agents,
targeting the following neurotransmitter systems:
(i) The glutamatergic system: glycine, d-serine, d-cycloserine, CX516,
amantadine, memantine, pregnenolone, minocycline, l-carnosine,
lamotrigine, benzoate, Org 25935, sarcosine;
(ii) The cholinergic system: nicotine, donepezil, rivastigmine, galanta-
mine, DMXB-A, tropisetron, varenicline, AZD3480, TC-5619, ABT-126;
(iii) The serotonergic system: tandospirone, mianserin, mirtazapine,
citalopram, buspirone, ondansetron, duloxetine, latrepirdine, fluvox-
amine, ANV-211;
(iv) The dopaminergic system: d-amphetamine, entacapone, DAR-
0100A;
(v) The GABA-ergic system: MK-0777;
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(vi) The noradrenergic system: atomoxetine, reboxetine, guanfacine;
(vii) Miscellaneous-including agents that do not specifically target the
aforementioned neurotransmitter systems, or that target multiple
systems, or for which the exact target system is not well known:
davunetide, rosiglitazone, raloxifene, sildenafil, armodafinil,
modafinil.
Literature search
The meta-analysis was performed according to the Preferred Reporting for
Systematic Reviews and Meta-analysis (PRISMA) Statement.34 A systematic
search for studies published in peer-reviewed journals was conducted in
PubMed (Medline), Psychinfo, EmBase and Cochrane Database of
Systematic Reviews.
Combinations of the following search terms were used: ‘‘schizophrenia’’,
‘‘schizoaffective’’, ‘‘schizophreniform’’, ‘‘psychosis’’, ‘‘cognition’’, ‘‘cognitive’’,
‘‘enhancers’’, ‘‘enhancement’’, ‘‘glutamatergic’’, ‘‘glutamate’’, ‘‘NMDA’’,
‘‘AMPA’’, ‘‘cholinergic’’, ‘‘acetylcholine’’, ‘‘acetylcholinesterase’’, ‘‘nicotiner-
gic’’, ‘‘muscarinergic’’, ‘‘serotonin’’, ‘‘serotonergic’’, ‘‘dopamine’’, ‘‘dopami-
nergic’’ ‘‘D1’’, ‘‘COMT’’, ‘‘noradrenaline’’, ‘‘noradrenergic’’, ‘‘GABA-ergic’’,
‘‘GABA’’, and the individual names of cognitive enhancers as mentioned in
2.1, with no year or language limits. The literature search was conducted
by three authors (C.R., J.D.J., and S.M.), where at least two of them searched
independently for relevant publications. Titles, abstracts, and then relevant
full-text papers were examined. Consensus was reached between the
authors in cases of discrepancy. Cross references from the relevant papers
were searched for additional publications. If necessary, corresponding




1. Randomized, placebo-controlled studies measuring the effect of
pharmacological agents on cognition.
2. Studies including patients with schizophrenia, schizophreniform,
schizoaffective, delusional, or psychotic disorder not otherwise
specified according to the diagnostic criteria of the Diagnostic and
Statistical Manual of mental Disorders (DSM-III[-R], DSM-IV[R], DSM-
V), or the International Classification of Diseases (ICD-9 or -10).
3. Cognitive functioning is measured with neuropsychological tests.
4. Studies reporting sufficient information to compute common effect
size (ES) statistics (i.e., means, mean changes, SDs, exact F-, p-, t-, or
z-values) or corresponding authors provided these data upon
request.
Exclusion criteria.
1. Studies evaluating cognition solely based on more subjective
measures, such as an item from the PANSS (Positive and Negative
Syndrome Scale)35 interview.
2. Studies investigating a combination of two interventions, where the
non-pharmacological enhancer component of the intervention was
not controlled for in the control condition (e.g., pharmacological
enhancer+ cognitive training vs. placebo).
3. Studies providing post-means only.
4. In case of multiple reports from the same study only one was
included.
5. Although antipsychotic medication may also have a positive effect
on cognition, this class of drugs was not included in this review as
they are generally not taken to belong to the group of “cognitive
enhancers”.
Outcome measures
The current meta-analysis focused on cognitive outcomes specifically. First,
we evaluated the effects of cognitive enhancers on overall cognition by
including composite scores as provided by a cognitive test battery (for
example Brief Assessment of Cognition in Schizophrenia (BACS)36 total
score or MATRICS Consensus Cognitive Battery (MCCB)37 total score) or as
calculated by the authors. Second, individual neuropsychological tests
were grouped into seven cognitive domains, relevant for schizophrenia: 1.
attention/vigilance, 2. processing speed (PS), 3. reasoning, 4. verbal
learning and memory, 5. visual learning and memory, and 6. working
memory (WM) [as recommended by MATRICS (Measurement and
Treatment Research to Improve Cognition in Schizophrenia)], in addition
to 7. verbal fluency (as measured by the majority of included studies).
When a study applied multiple cognitive tests to assess the same cognitive
domain, the primary outcome measure as defined by the authors was
included in the meta-analysis. When the authors did not define the primary
outcome, we selected the test most relevant to our defined cognitive
domains. If studies reported multiple outcomes for a single cognitive test
(for example, the Wisconsin Card Sorting Task (WCST) resulting in the
number of completed categories, but also preservative errors), the
outcome most commonly used across studies was used.
Analyses and sub-analyses
In the overall analyses, whenever possible all identified study samples were
included for each of the defined outcome measures (i.e., cognitive
domains). Subsequently, study samples were grouped according to the
neurotransmitter system of the cognitive enhancer studied (as described in
section 2.1). Sub-analyses for pharmacological agents acting on the same
or relevant pathway were conducted only when at least three different
studies were identified, and by grouping the study samples for each
specific/relevant pathway.
Calculations
Effect sizes were computed using Comprehensive Meta-Analysis Version
2.0, Biostat.38 Hedges’s g was used to quantify effect sizes (ES) for the mean
difference between change scores (end of treatment minus baseline) of
the intervention group vs. placebo group. Although change scores are
subject to increased error variance, we preferred these over pre- and post-
treatment scores to avoid overestimation of the true effect size because of
the pre- and -post-treatment correlation. When change scores were not
provided by the authors, pre- and post-treatment scores were used. If not
reported, pre- and post-treatment means and standard deviations (SDs), or
exact F-, t- or p-values were used. Some studies had more than one follow-
up time-point. Therefore, the last follow-up time-point of active treatment
of the study sample was used. Single dose (i.e., challenge) studies were
included only if they had pre- and post-assessments and analyses were run
with and without these studies. Studies with multiple treatment groups
(for example, different doses) and one placebo group were entered as
individual study samples (k). As these treatment groups are dependent due
to sharing a control group and the effective sample size is inflated,38
analyses that yielded significant results were repeated by splitting the
shared placebo group into two or three groups with smaller sample size.
Studies were combined to calculate a mean weighted ES for each
cognitive outcome measure, using a random effects model. Effect sizes
were interpreted according to Cohen,39 with an ES of 0.2 indicating a small,
0.5 medium, and > 0.8 a large effect. To investigate whether studies could
be combined to share a common population effect size, the Q-value and
I2–statistic were evaluated for each analysis. The Q-statistic tests the
existence of heterogeneity, and displays a chi-square distribution with k-1
degrees of freedom (k= number of studies), where Q-values higher than
the degrees of freedom indicate significant between-studies variability. I2
reflects which proportion of the observed variance reflects differences in
true effect sizes rather than sampling error, ranging from 0 to 100%. Values
of 25%, 50%, and 75% can be interpreted as low, moderate, and high,
respectively.40 Potential outlier studies were evaluated when heterogene-
ity exceeded 50%, which were defined as standardized residual z‐scores of
effect sizes exceeding ± 1.96 (p < 0.05, two-tailed).
When interpreting meta-analytic outcomes, the possibility of an upward
bias of the calculated effect sizes due to the omission of unpublished,
nonsignificant studies must be taken into account.41 Potential publication
bias was investigated by means of a visual inspection of the funnel plot
and Egger’s test42 was evaluated when appropriate (i.e., analysis included a
range of study sizes, with at least one of ‘‘medium’’ size (p < .05 two-tailed).
Moreover, the fail-safe number of studies (NR) was calculated, providing an
estimate of how many unpublished null findings would be needed to
reduce an observed overall significant result to nonsignificance (the fail-
safe number should be 5k+ 10 or higher (k= number of studies in a meta-
analysis) to rule out a file drawer problem.41
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